Danish pharmaceutical giant Novo Nordisk has launched Awiqli (insulin icodec) in India, introducing the world's first once-weekly basal insulin for adults with Type 1 and Type 2 diabetes. The launch marks a major advancement in diabetes care by reducing the number of insulin injections from 365 per year to just 52, potentially improving treatment adherence among millions of patients.

The U.S. Food and Drug Administration (FDA) has proposed a major overhaul of its drug establishment registration and drug listing regulations, aiming to modernize oversight of pharmaceutical manufacturing and improve visibility across global supply chains. If finalized, the rule would introduce a new regulatory framework for distributed manufacturing and expand registration requirements for certain foreign drug manufacturing establishments that currently fall outside existing regulations.